A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
NewAmsterdam Pharma said regulatory decisions on obicetrapib in Europe, the UK and Switzerland remain expected in 2H26. PREVAIL interim analysis is planned for 4Q2026, with a result expected in 1Q2027.
LIB Therapeutics launched Lerochol in the United States after FDA approval for lowering LDL-C in adults with hypercholesterolemia, including HeFH. The once-monthly PCSK9 inhibitor is available with a $199-per-month cash-pay option.
Research in the United Kingdom found that preventing type 2 diabetes cut care-related greenhouse gas emissions by about 67%, while well-controlled disease was linked to 21% lower emissions than uncontrolled diabetes.
C-peptide is described as a key biomarker for beta cell function in type 1 diabetes and a potential surrogate endpoint for drug approval. Current trial endpoints remain difficult for disease-modifying therapies.
mRNA medicine and spatiotemporal drug delivery systems are expanding options for cardiovascular disease. The sources describe preclinical proof-of-concept, clinical trials and programmable cardiac repair platforms.
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
Ray Therapeutics received EMA PRIME designation for its RTx-015 optogenetic gene therapy for retinitis pigmentosa, following recent FDA RMAT status. The company also appointed Michael Murtagh as Chief Regulatory Officer to support global development.
A study in the American Journal of Medicine found that U.S. adults with the highest ultraprocessed food intake had higher cardiovascular disease risk. Mean ultraprocessed food intake was 26.1% of total energy.
Diabetes and heart disease can impair sexual function by damaging blood vessels, nerves and circulation. Sexual dysfunction may also be an early warning sign of underlying vascular damage.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07578090 |
Regional Innovation in Chronic Disease and Elderly Care |
NOT_YET_RECRUITING | |
| NCT07521436 |
Awareness of Risk Factors and Perception of Cardiovascular Risk in Secondary Prevention Among Women and Men |
RECRUITING | |
| NCT07518719 |
Feasibility of The Health Integrated Nutrition and Kidney Wellness Program |
NOT_YET_RECRUITING | NA |
| NCT07507409 |
Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients |
NOT_YET_RECRUITING | PHASE4 |
| NCT07500948 |
Effectiveness of Pollution Monitoring in Clinical Exercise Rehabilitation |
NOT_YET_RECRUITING | NA |
| NCT07497932 |
Nutritional Effects in Cardiovascular Surgery |
RECRUITING | NA |
| NCT07485283 |
Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia |
RECRUITING | PHASE4 |
| NCT07481825 |
Impact of Combined Cardio-pulmonary Assessment on COPD Clinical Management. |
NOT_YET_RECRUITING | NA |
| NCT07466056 |
Application of Non-inductive Intelligent Physical Sign Monitoring Equipment Based on Flexible Electronic Devices in the Diagnosis and Treatment of Cardiovascular Diseases |
RECRUITING | |
| NCT07431515 |
Long-term Risk of Cardiovascular Disease in Living Kidney Donors |
COMPLETED |
